查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1863650

全球心房顫動市場：按類型、技術、療法、終端用戶和地區劃分 - 市場規模、行業趨勢、機會分析和預測（2025-2033 年）

Global Atrial Fibrillation Market: By Type, By Technology, By Treatment, By End User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

受創新診斷和治療方案需求不斷增長的驅動，房顫市場正在快速發展。 2024 年，該市場收入約為 37.3209 億美元，反映出心房顫動盛行率的上升以及先進醫療技術的日益普及。預計這一成長趨勢將持續強勁，到 2033 年，市場規模預計將達到 79.1366 億美元。這一顯著增長意味著 2025 年至 2033 年的複合年增長率 (CAGR) 為 8.71%。

推動這一成長的關鍵因素之一是對主動偵測方法的重視，這些方法對於更有效地管理心房顫動至關重要。配備先進感測器和人工智慧診斷工具的可穿戴監測設備正在改變這種疾病的識別和監測方式。這些技術能夠持續、即時地追蹤心律，從而實現早期診斷和及時幹預，避免併發症的發生。

市場動態

心房顫動 (AF) 市場競爭異常激烈，美敦力、波士頓科學和雅培等行業領導者不斷透過各種策略措施來維持和擴大市場佔有率。這些公司積極推出創新產品、進行收購並建立合作關係，以鞏固其在這個快速發展領域中的地位。

例如，2025 年 5 月，全球醫療保健領導者雅培宣布推出 TactiFlex 感測器消融導管。該設備是世界上首款將柔性尖端與先進接觸力技術結合的消融導管。該產品的創新之處在於提高了導管消融手術的精準性和安全性，該手術旨在靶向並消除異常電通路，是治療心律不整的關鍵。

同樣，強生醫療科技於2025年7月在亞太地區推出了VARIPULSE™平台，進一步拓展了其業務。該平台專為執行導管消融手術而設計，用於治療心房顫動。心房顫動是一種常見的心律不整，其特徵是由於心房內電訊號紊亂而導致的心跳不規則且通常過快。

主要成長推動因素

推動心房顫動市場成長的關鍵因素之一是左心耳封堵術（LAAO）裝置作為一種非藥物治療方法在預防中風方面的快速普及。這些裝置為中風高風險患者或有長期抗凝血治療禁忌症或不耐受的患者提供了一種替代方案。左心耳封堵術 (LAAO) 技術的日益普及體現在手術數量的顯著增長上，預計僅 2024 年就將進行 10 萬例 LAAO 手術。這一激增反映了臨床醫生和患者對這些設備的有效性和安全性越來越有信心。

新興機會

穿戴式健康監測技術的快速普及為心房顫動市場帶來了巨大的機會。蘋果和三星等領先的科技公司正在開發配備先進感測器和尖端人工智慧演算法的設備，從而實現房顫的早期檢測。這些創新正在改變傳統的健康監測方式，直接向使用者提供連續的即時數據，從而能夠及早識別那些可能直到出現更嚴重症狀才會被發現的心律不整。

優化障礙

心房顫動市場面臨的重大挑戰之一是確保患者能夠公平地獲得先進的消融技術。雖然這些先進療法療效顯著，但費用高昂，這可能會限制某些患者群體獲得治療的機會，尤其是在醫療預算緊張或保險覆蓋不足的地區。先進消融設備和手術的高昂價格可能會造成治療機會不均等，使一些患者無法受益於最新的醫療技術。

目錄

第一章：研究架構

  • 研究目標
  • 產品概述
  • 市場區隔

第二章：研究方法

  • 質性研究
    • 一手和二手資料來源
  • 量化研究
    • 一手和二手資料來源
  • 按地區劃分的一手調查受訪者組成
  • 研究假設
  • 市場規模估算
  • 資料三角驗證

第三章：摘要整理：全球心房顫動市場

第四章：全球心房顫動市場概述

  • 產業價值鏈分析
    • 設備供應商
    • 製造商
    • 經銷商
    • 最終用戶
  • 行業展望
    • 新興技術
    • 各國病例總數
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場動態與趨勢
    • 成長推動因素
    • 阻礙因素
    • 挑戰
    • 主要趨勢
  • 新冠疫情對市場的影響評估成長趨勢
  • 市場成長與展望
    • 市場收入估計與預測（2020-2033 年）
    • 價格趨勢分析
  • 競爭格局概覽
    • 市場集中度
    • 公司市佔率分析（價值，2024 年）
    • 競爭格局圖

第五章 全球心房顫動市場分析：依類型劃分

  • 主要見解
  • 市場規模與預測（2020-2033 年）
    • 陣發性心房顫
    • 持續性心房顫
    • 慢性/永久性心房顫動

第六章：全球心房顫動市場分析：依技術劃分

  • 主要見解
  • 市場規模及預測，2020-2033
    • MicroLife AFIB 技術
    • 混合外科導管消融術
    • 冷凍療法

第七章：全球心房顫動市場按療法劃分的分析

  • 主要見解
  • 市場規模及預測，2020-2033
    • 診斷
    • 藥物治療

第八章：全球心房顫動市場按最終用戶劃分的分析

  • 主要見解
  • 市場規模及預測，2020-2033
    • 醫院
    • 護理中心
    • 門診
    • 門診護理服務

第九章 全球心房顫動市場：依地區劃分

  • 主要見解
  • 市場規模及預測，2020-2033 年
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲 (MEA)
    • 南美

第十章：北美心房顫動市場分析

  • 主要見解
  • 市場規模及預測，2020-2033 年
    • 依類型
    • 按技術
    • 依療法
    • 按最終用戶
    • 依國家/地區

第十一章：歐洲心房顫動市場分析

第十二章：亞太地區心房顫動市場分析

第十三章：中東與非洲心房顫動市場分析

第十四章：南美洲心房顫動市場分析

第15章 企業簡介

  • AtriCure Inc.
  • Biosense Webster Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus Inc.
  • Endoscopic Technologies Inc.
  • Johnson & Johnson Ltd.
  • Koninklijke Philips N.V.
  • MicroPort Scientific Corporation
  • Sanofi-Aventis
  • Siemens AG
  • St. Jude Medical Inc.
  • Other Prominent Players
簡介目錄
Product Code: AA1222338

The atrial fibrillation market is experiencing rapid advancement, driven by increasing demand for innovative diagnostic and treatment solutions. In 2024, the market generated revenue of approximately US$ 3,732.09 million, reflecting the growing prevalence of atrial fibrillation and the expanding adoption of advanced medical technologies. This upward trajectory is expected to continue strongly, with projections estimating the market will reach a valuation of US$ 7,913.66 million by 2033. This remarkable growth corresponds to a compound annual growth rate (CAGR) of 8.71% during the forecast period from 2025 to 2033.

One of the key factors driving this growth is the prioritization of proactive detection methods, which are becoming integral to managing atrial fibrillation more effectively. Wearable monitors equipped with sophisticated sensors and artificial intelligence-powered diagnostic tools are transforming how the condition is identified and monitored. These technologies enable continuous, real-time tracking of cardiac rhythms, allowing for earlier diagnosis and timely intervention before complications arise.

Noteworthy Market Developments

The atrial fibrillation (AF) market is highly competitive, with major industry players such as Medtronic, Boston Scientific, and Abbott continually striving to maintain and expand their market share through a range of strategic initiatives. These companies actively engage in launching innovative products, pursuing acquisitions, and forming partnerships to strengthen their positions in this rapidly evolving sector.

For example, in May 2025, Abbott, a global healthcare leader, announced the launch of the TactiFlex Sensor-Enabled Ablation Catheter. This device is notable for being the world's first ablation catheter to combine a flexible tip with advanced contact force technology. The innovation behind this product enhances the precision and safety of catheter ablation procedures, which are critical for treating atrial fibrillation by targeting and eliminating the abnormal electrical pathways.

In a similar move, Johnson & Johnson MedTech expanded its footprint in the Asia-Pacific region in July 2025 with the launch of the VARIPULSE(TM) Platform. This platform is designed specifically for performing catheter ablation procedures to treat atrial fibrillation, a common cardiac arrhythmia characterized by irregular and often rapid heartbeats caused by uncoordinated electrical signals in the atria.

Core Growth Drivers

A significant driver propelling growth in the atrial fibrillation market is the rapid adoption of Left Atrial Appendage Occlusion (LAAO) devices as a non-pharmacological approach to stroke prevention. These devices offer an alternative for patients who are at high risk of stroke but may have contraindications or intolerance to long-term anticoagulant therapy. The increasing acceptance of LAAO technology is reflected in the substantial number of procedures performed, with an estimated 100,000 LAAO interventions carried out in 2024 alone. This surge underscores the growing confidence among clinicians and patients in the efficacy and safety of these devices.

Emerging Opportunity Trends

A significant opportunity within the atrial fibrillation market arises from the rapid consumer adoption of wearable technology designed for health monitoring. Leading technology companies such as Apple and Samsung have developed devices equipped with sophisticated sensors and advanced AI-driven algorithms capable of detecting atrial fibrillation at an early stage. These innovations transform traditional health monitoring by providing continuous, real-time data directly to users, enabling early identification of irregular heart rhythms that might otherwise go unnoticed until more severe symptoms emerge.

Barriers to Optimization

One of the significant challenges facing the atrial fibrillation market is ensuring equitable patient access to advanced ablation technologies, which are often expensive. These cutting-edge treatment options, while highly effective, come with substantial costs that can limit their availability to certain patient populations, particularly in regions with constrained healthcare budgets or inadequate insurance coverage. The high price point of advanced ablation devices and procedures may create disparities in treatment accessibility, preventing some patients from benefiting from the latest medical innovations.

Detailed Market Segmentation

By Type, the Chronic/Permanent Afib segment is projected to secure a commanding 48.6% share of the atrial fibrillation market, reflecting its significant impact on the overall disease burden. This dominance is closely linked to demographic trends, particularly the aging global population. As people age, the likelihood of atrial fibrillation progressing from intermittent or paroxysmal episodes to a chronic or permanent condition increases substantially. This progression is due to structural and electrical changes in the heart that accumulate over time, making permanent Afib more prevalent among older adults.

By Technology, cryotherapy is poised to dominate the atrial fibrillation market, commanding a significant 53.7% share. This strong position is largely driven by its compelling value proposition, which combines procedural efficiency with enhanced safety profiles. Cryotherapy, particularly in the form of cryoballoon ablation, has gained widespread acceptance among electrophysiologists and hospital administrators alike because it offers a highly effective treatment option that reduces the duration of procedures without compromising patient outcomes.

By Treatment, the diagnosis segment continues to hold a commanding lead in the atrial fibrillation market, accounting for over 68.7% of the total share. This dominant position reflects a broader strategic shift within the healthcare industry towards preventative care, emphasizing the importance of early and accurate detection to improve patient outcomes. Detecting atrial fibrillation at an early stage is critical, as it allows for timely intervention that can prevent severe and costly complications, such as stroke and heart failure, which are common consequences of untreated or late-diagnosed atrial fibrillation.

By End User, hospitals are poised to maintain their dominant role as the primary end-user in the atrial fibrillation market, effectively serving the vast majority of treatment demand for this condition. Their leading position is largely due to their capacity to provide the most complex and high-value interventions, particularly catheter ablation procedures, which require specialized equipment and highly trained medical teams. These advanced treatments are typically only available in hospital settings, where comprehensive care can be delivered safely and efficiently. As a result, hospitals remain the central hubs for managing atrial fibrillation, offering a wide range of services from diagnosis to advanced therapeutic interventions.

Segment Breakdown

By Type

  • Paroxysmal Afib
  • Persistent Afib
  • Chronic/Permanent Afib

By Technology

  • Microlife AFIB Technology
  • Hybrid Surgical-Catheter Ablation
  • Cryotherapy

By Treatment

  • Diagnosis
  • Electrocardiogram
  • Blood tests
  • Echocardiogram
  • Chest X-ray
  • Other (Blood tests)
  • Medication
  • Anticoagulants
  • Others

By End User

  • Hospitals
  • Care Centers
  • Outpatients
  • Ambulatory Services

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Geography Breakdown

  • North America holds a commanding position in the global atrial fibrillation market, accounting for over 39% of the total market share. This dominant stance is largely attributed to the region's substantial healthcare spending, which supports widespread access to advanced treatments and diagnostic technologies. The high procedural volumes in North America reflect a well-established healthcare system that is both capable and equipped to manage the growing number of atrial fibrillation cases. Additionally, the region benefits from a sophisticated healthcare infrastructure, including state-of-the-art medical facilities and a highly skilled workforce of cardiologists, electrophysiologists, and support staff.
  • Within North America, the United States stands out as the largest contributor to the market in 2024. This leadership is driven by several critical factors, foremost among them being the high incidence of atrial fibrillation cases in the country's aging population. The U.S. healthcare system has rapidly embraced minimally invasive ablation technologies, which have become the preferred treatment option due to their effectiveness and reduced recovery times. Furthermore, robust clinical guidelines in the U.S. strongly support early intervention for atrial fibrillation, encouraging timely diagnosis and treatment to prevent complications such as stroke and heart failure.

Leading Market Participants

  • Atri Cure Inc.
  • Biosense Webster Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus Inc.
  • Endoscopic Technologies Inc.
  • Johnson & Johnson Ltd.
  • Koninklijke Philips N.V.
  • MicroPort Scientific Corporation
  • Sanofi-Aventis
  • Siemens AG
  • St. Jude Medical Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1 Research Objective
  • 1.2 Product Overview
  • 1.3 Market Segmentation

Chapter 2. Research Methodology

  • 2.1 Qualitative Research
    • 2.1.1 Primary & Secondary Sources
  • 2.2 Quantitative Research
    • 2.2.1 Primary & Secondary Sources
  • 2.3 Breakdown of Primary Research Respondents, By Region
  • 2.4 Assumption for the Study
  • 2.5 Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Atrial Fibrillation Market

Chapter 4. Global Atrial Fibrillation Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Equipment Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributor
    • 4.1.4. End User
  • 4.2. Industry Outlook
    • 4.2.1. Emerging Technologies
    • 4.2.2. Total Number of Cases, By Country
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
    • 4.7.3. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Atrial Fibrillation Market Analysis, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Paroxysmal Afib
    • 5.2.2. Persistent Afib
    • 5.2.3 Chronic/Permanent Afib

Chapter 6. Global Atrial Fibrillation Market Analysis, By Technology

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. Microlife AFIB Technology
    • 6.2.2. Hybrid Surgical-Catheter Ablation
    • 6.2.3. Cryotherapy

Chapter 7. Global Atrial Fibrillation Market Analysis, By Treatment

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Diagnosis
      • 7.2.1.1. Electrocardiogram
      • 7.2.1.2. Blood tests
      • 7.2.1.3. Echocardiogram
      • 7.2.1.4. Chest X-ray
      • 7.2.1.5. Other (Blood tests)
    • 7.2.2. Medication
      • 7.2.2.1. Anticoagulants
      • 7.2.2.2. Others

Chapter 8. Global Atrial Fibrillation Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Hospitals
    • 8.2.2. Care Centers
    • 8.2.3. Outpatients
    • 8.2.4. Ambulatory Services

Chapter 9. Global Atrial Fibrillation Market, By Region

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. North America
      • 9.2.1.1. The U.S.
      • 9.2.1.2. Canada
      • 9.2.1.3. Mexico
    • 9.2.2. Europe
      • 9.2.2.1. Western Europe
        • 9.2.2.1.1. The UK
        • 9.2.2.1.2. Germany
        • 9.2.2.1.3. France
        • 9.2.2.1.4. Italy
        • 9.2.2.1.5. Spain
        • 9.2.2.1.6. Rest of Western Europe
      • 9.2.2.2. Eastern Europe
        • 9.2.2.2.1. Poland
        • 9.2.2.2.2. Russia
        • 9.2.2.2.3. Rest of Eastern Europe
    • 9.2.3. Asia Pacific
      • 9.2.3.1. China
      • 9.2.3.2. India
      • 9.2.3.3. Japan
      • 9.2.3.4. Australia & New Zealand
      • 9.2.3.5. ASEAN
      • 9.2.3.6. Rest of Asia Pacific
    • 9.2.4. Middle East & Africa (MEA)
      • 9.2.4.1. UAE
      • 9.2.4.2. Saudi Arabia
      • 9.2.4.3. South Africa
      • 9.2.4.4. Rest of MEA
    • 9.2.5. South America
      • 9.2.5.1. Brazil
      • 9.2.5.2. Argentina
      • 9.2.5.3. Rest of South America

Chapter 10.North America Atrial Fibrillation Market Analysis

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Treatment
    • 10.2.4. By End User
    • 10.2.5. By Country

Chapter 11. Europe Atrial Fibrillation Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 11.2.1. By Type
    • 11.2.2. By Technology
    • 11.2.3. By Treatment
    • 11.2.4. By End User
    • 11.2.5. By Country

Chapter 12. Asia Pacific Atrial Fibrillation Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Type
    • 12.2.2. By Technology
    • 12.2.3. By Treatment
    • 12.2.4. By End User
    • 12.2.5. By Country

Chapter 13. Middle East & Africa Atrial Fibrillation Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Type
    • 13.2.2. By Technology
    • 13.2.3. By Treatment
    • 13.2.4. By End User
    • 13.2.5. By Country

Chapter 14. South America Atrial Fibrillation Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Type
    • 14.2.2. By Technology
    • 14.2.3. By Treatment
    • 14.2.4. By End User
    • 14.2.5. By Country

Chapter 15. Company Profile (Company Overview, Sales Composition Ratio, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 15.1. AtriCure Inc.
  • 15.2. Biosense Webster Inc.
  • 15.3. Boehringer Ingelheim GmbH
  • 15.4. Boston Scientific Corporation
  • 15.5. Bristol-Myers Squibb Corporation
  • 15.6. CardioFocus Inc.
  • 15.7. Endoscopic Technologies Inc.
  • 15.8. Johnson & Johnson Ltd.
  • 15.9. Koninklijke Philips N.V.
  • 15.10. MicroPort Scientific Corporation
  • 15.11. Sanofi-Aventis
  • 15.12. Siemens AG
  • 15.13. St. Jude Medical Inc.
  • 15.14. Other Prominent Players